


Deferasirox (Fe<sup>3+</sup> chelate)

## Chemical Properties

CAS No. :	554435-83-5
Formula:	C <sub>21</sub> H <sub>12</sub> FeN <sub>3</sub> O <sub>4</sub>
Molecular Weight:	426.18
Appearance:	no data available
Storage:	store at low temperature
	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	Deferasirox (Fe <sup>3+</sup> chelate) is an orally available iron chelator with potential anticancer activity, inhibits the anti-apoptotic activity of MCL-1, and can be used to study iron overload.
Targets(IC50)	Apoptosis
In vitro	Deferasirox (Fe <sup>3+</sup> chelate) promotes cell cycle arrest in cervical cancer cell lines by regulating the expression of cell cycle regulatory factors cyclin D1, cyclin E, and proliferating cell nuclear antigen (PCNA)[1].

## Solubility Information

Solubility	DMSO: 30 mg/mL (70.39 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3464 mL	11.7321 mL	23.4643 mL
5 mM	0.4693 mL	2.3464 mL	4.6929 mL
10 mM	0.2346 mL	1.1732 mL	2.3464 mL
50 mM	0.0469 mL	0.2346 mL	0.4693 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

- Zhou N, et al. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo. *Gynecol Oncol*. 2022 Jul;166(1):126-137.
- Ishimaru K, et al. Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A. *J Am Heart Assoc*. 2024 Jan 2;13(1):e031219.
- Sedgwick AC, et al. Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties. *J Am Chem Soc*. 2021 Jan 27;143(3):1278-1283.
- Babu T, et al. Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review. *Indian J Pharmacol*. 2020 Nov-Dec;52(6):514-519.
- Kwan P, et al. Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models. *Biomolecules*. 2022 Feb 25;12(3):365.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286    E\_mail: info@targetmol.com    Address: 36 Washington Street, Wellesley Hills, MA 02481